Optimizing the Dosing of Intravenous Theophylline in Acute Severe Asthma in Children

Area of Science:

• Pediatric Emergency Medicine
• Clinical Pharmacology
• Respiratory Medicine

Background:

• Acute severe asthma in children necessitates optimized management to reduce hospitalizations and mortality.
• Intravenous theophylline (aminophylline) is a second-line treatment for life-threatening pediatric asthma exacerbations.

Purpose of the Study:

• To critically evaluate the evidence supporting current intravenous theophylline dosing recommendations for acute severe asthma in children.
• To identify knowledge gaps regarding the relationship between serum theophylline concentrations, administered dose, and clinical response.

Main Methods:

• Systematic review of existing literature on intravenous theophylline use in pediatric severe asthma.
• Analysis of current guidelines and formularies for recommended dosing regimens.
• Assessment of the evidence linking serum concentrations to clinical efficacy and adverse events.

Main Results:

• Current recommendations for intravenous theophylline (aminophylline) dosing in children with severe asthma are based on limited evidence.
• There is a significant lack of understanding regarding the correlation between achieved serum concentrations, administered doses, and actual clinical improvement.
• Existing guidelines suggest a therapeutic range of 10-20 mg/L, but the data supporting this is insufficient.

Conclusions:

• Further research is crucial to establish optimal intravenous theophylline dosing strategies for pediatric severe asthma.
• Proposed research should focus on improving severity assessment, dose optimization, adverse event monitoring, and understanding inter-individual response variability.
• Enhanced evidence is needed to improve treatment efficacy and safety for children with severe asthma requiring intravenous theophylline.